Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis

Clicks: 338
ID: 266758
2009
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1 of 109 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
End-stage renal disease (ESRD) due to hypertension is common and displays familial aggregation in African Americans, suggesting genetic risk factors, including adrenergic activity alterations which are noted in both hypertension and ESRD. We analysed 554 hypertensive nephrosclerosis participants (without clinically significant proteinuria) from the longitudinal National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) African American Study of Kidney Disease and Hypertension (AASK) cohort to determine whether decline in glomerular filtration rate (GFR) over approximately 3.8 years was predicted by common genetic variation within the adrenergic beta-1 (ADRB1) receptor at non-synonymous positions Ser49Gly and Arg389Gly. The polymorphism at Ser49Gly (though not Arg389Gly, in only partial linkage disequilibrium at r(2) = 0.18) predicted the chronic rate of GFR decline, with minimal decline in Gly(49)/Gly(49) (minor allele) homozygotes compared to Ser(49) carriers; concordant results were observed for haplotypes and diploid haplotype pairs at the locus. An independent replication study in 1244 subjects from the San Diego Veterans Affairs Hypertension Cohort confirmed that Gly(49)/Gly(49) homozygotes displayed the least rapid decline of eGFR over approximately 3.6 years. We conclude that GFR decline rate in hypertensive renal disease is controlled in part by genetic variation within the adrenergic pathway, particularly at ADRB1. The results suggest novel strategies to approach the role of the adrenergic system in the risk and treatment of progressive renal disease.
Reference Key
co-investigators2009nephrologyadrenergic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors M. M. Fung,Y. Chen,M. S. Lipkowitz,R. M. Salem,V. Bhatnagar,M. Mahata,C. M. Nievergelt,F. Rao,S. K. Mahata,N. J. Schork,V. H. Brophy,D. T. O'Connor,for the AASK Co-Investigators;M. M. Fung;Y. Chen;M. S. Lipkowitz;R. M. Salem;V. Bhatnagar;M. Mahata;C. M. Nievergelt;F. Rao;S. K. Mahata;N. J. Schork;V. H. Brophy;D. T. O'Connor;for the AASK Co-Investigators;
Journal nephrology dialysis transplantation
Year 2009
DOI
10.1093/ndt/gfp471
URL
https://sciprofiles.com/publication/view/0d7218428630b1ec7b1d3d8dc216105f
Keywords
african americans kidney disease sympathetic nervous system glomerular filtration rate aask

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.